Startups
Parithera’s goal is to save lives by providing a minimally invasive diagnostic which analyses cancer treatment resistance and allows clinicians to adjust treatment regimen.
Overview
Location
Switzerland, Vaud, Lausanne
Employees
1-10
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 11, 2025 | Switzerland: The New Frontier of AI and Precision Oncology | Switzerland is not just about chocolate and watches. It’s a rising star in the tech world, especially in artificial intelligence (AI) and precision oncology. Two recent developments highlight this transformation: the launch of the AI TALK p... |
| May 8, 2025 | Parithera ExTrace Platform makes strong impression in Chicago | A few days ago at AACR (American Association for Cancer Research) Conference in Chicago, Biopôle-based Parithera presented the first results of its groundbreaking ExTrace platform to detect and analyze circulating tumor cells (CTCs), pione... |
| Feb 3, 2023 | Volumina Medical, Parithera and PeriVision win Biopôle Funding | |
| May 9, 2022 | Startup internationalisation camp in the US in progress | |
| Mar 22, 2022 | CHF 100’000 for Parithera ExTrace Dx Cancer Tracking | Despite the progress medicine has undergone in the last decades, cancer patients are not given equal chances to benefit from the most suitable treatments. For example, immunotherapies do not represent a cure for most patients, and tissue bi... |
| May 17, 2021 | MassChallenge Switzerland Cohort 2021 on the starting blocks | |
| May 17, 2021 | MassChallenge Switzerland Announces 6th Cohort | May 17, 2021 (Renens, Switzerland) - MassChallenge Switzerland, part of MassChallenge’s global network of innovators, today announced the 97 early-stage startups invited to join the 2021 Accelerator Program. These selected startups have be... |
| May 17, 2021 | MassChallenge Switzerland Cohort 2021 on the starting blocks | For the 2021 program the MassChallenge Switzerland team has designed an on-line / on-site hybrid accelerator program. The startups come from 31 countries spanning over 4 continents and have the potential to create widespread impact across i... |
| Jan 21, 2021 | CHF 40,000 for startups revolutionizing G protein coupled receptors screening, developing tracers for early detection of neurological diseases, and precision diagnostics for cancer treatment | ArcoScreen: revolutionizing G protein coupled receptors screening G protein coupled receptors (GPCRs) are the most successful drug targets to treat diseases like cancer, Parkinson’s or Alzheimer’s. Current assays to find new drugs are limit... |
Show more
Reviews 0
FAQ about Parithera
What has the press written about Parithera?
Parsers VC has collected 11 articles mentioning Parithera, among them “Switzerland: The New Frontier of AI and Precision Oncology” (May 11, 2025) and “Parithera ExTrace Platform makes strong impression in Chicago” (May 8, 2025).
Is Parithera still active?
Yes, Parithera is active; its latest activity on Parsers VC dates from Aug 22, 2025.